Portal de Periódicos da CAPES

Aseptic Meningitis and Intravenous Immunoglobulin Therapy

1995; American College of Physicians; Volume: 122; Issue: 4 Linguagem: Inglês

10.7326/0003-4819-122-4-199502150-00021

1539-3704

Marinos C. Dalakas,

Pneumocystis jirovecii pneumonia detection and treatment

Letters15 February 1995Aseptic Meningitis and Intravenous Immunoglobulin TherapyMarinos C. DalakasMarinos C. DalakasSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-4-199502150-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:The products and lots of intravenous immunoglobulin preparations we used for patients 1 and 4 Table 1 of our article [1]) were 3 monthly infusions of the same lot of Gamimune 5% (Miles, Inc., West Haven, Connecticut); these patients developed aseptic meningitis after each infusion. Patient 1 received 14 additional twice monthly infusions, 6 with different lots of Gamimune and 8 with Gammagard (Baxter Healthcare, Glendale, California). He again developed aseptic meningitis after each infusion except with the last two. Patient 2 developed aseptic meningitis after receiving 1 infusion of Gamimune 5%; he subsequently received 13 monthly infusions ...References1. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994; 121:259-62. Google Scholar2. De Vlieghere FC, Peetermans WE, Vermylen J. Aseptic granulocytic meningitis following treatment with intravenous immunoglobulin. Clin Infect Dis. 1994; 18:1008-10. Google Scholar3. Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med. 1994; 121:305-6. Google Scholar4. Ronda N, Haury M, Nobrega A, Continhio A, Kazatchkine MD. Selectivity of recognition of variable regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopath. 1994; 70:124-8. Google Scholar5. Grosse-Wilde H, Blasczyk R, Westhoff V. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens. 1992; 39:74-7. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByImmunotherapy in the Treatment of Autoimmune Neuromuscular DiseasesThe use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profileImmunoglobulin for rheumatic diseases in the twenty-first centuryIntravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelinesACUTE ASEPTIC MENINGITIS SECONDARY TO INTRAVENOUS IMMUNOGLOBULIN IN A PATIENT WITH KAWASAKI SYNDROME 15 February 1995Volume 122, Issue 4Page: 316-317KeywordsBacterial meningitisHealth careHuman leukocyte antigenIdiopathic thrombocytopenic purpuraIntravenous immunoglobulinKawasaki diseaseLumbar punctureMeningitisSpecificitySubarachnoid hemorrhage Issue Published: 15 February 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...